10-Q · May 11, 2026
Biote Corp. reported Q1 2026 financial results with revenues of $44.9 million, representing a decline of 8.3% year-over-year and missing analyst expectations, while EPS was $0.06, falling short of the estimated $0.08.…
Earnings analysis · 10-Q
BTMD earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
BTMD reported Q2 2026 revenue of $44.232 million and diluted EPS of $(0.23), with revenue declining from both the prior quarter and prior-year quarter and EPS materially missing the $0.08 consensus estimate. The quarter…
Read full summary
BTMD reported Q2 2026 revenue of $44.232 million and diluted EPS of $(0.23), with revenue declining from both the prior quarter and prior-year quarter and EPS materially missing the $0.08 consensus estimate. The quarter also included a $5.1 million legal-settlement charge and continued share repurchases of $4.8 million. The most significant governance concern is that disclosure controls remained ineffective as of June 30, 2026 because the previously reported material weakness had not been remediated; management provided no quantitative guidance in the supplied 10-Q text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.23
What stood out
-
Revenue declined sequentially and year over year
Second-quarter revenue was $44.232 million, down from $45.0 million in Q1 2026 and $49.0 million in Q2 2025, a sequential decline of approximately 1.7% and year-over-year decline of approximately 9.7%.
-
EPS turned negative and missed estimates
Reported diluted EPS was $(0.23), versus $0.06 in Q1 2026 and $0.10 in Q2 2025. EPS missed the $0.08 consensus estimate by $0.31 per share.
-
Share repurchases continued
The company repurchased 2,436,177 Class A shares for $4.8 million during Q2 2026, at an average price of $2.05 per share.
-
Remaining buyback authorization
Approximately $5.2 million remained available under the $20.0 million share repurchase authorization as of June 30, 2026.
-
Right Value litigation payment completed
The company paid the remaining amount due under the $5.0 million Right Value settlement in February 2026, resolving that litigation subject to customary mutual releases.
What to watch
-
Material weakness remains unresolved
Disclosure controls were concluded to be ineffective as of June 30, 2026 because a previously reported material weakness remained unremediated. The weakness originated from insufficient technical accounting personnel and information-technology control deficiencies identified for fiscal years 2020 and 2019, and it contributed to errors in the June 30, 2022 and September 30, 2022 quarterly filings.
-
Settlement charges pressure results
The company recorded a $5.1 million charge for legal settlements in both the three and six months ended June 30, 2026; the amount was included in accrued liabilities at June 30, 2026.
-
Buybacks may constrain liquidity
The company repurchased 2,436,177 shares for $4.8 million in Q2 while reporting $(0.23) diluted EPS, leaving only $5.2 million under the authorization. Continued repurchases may reduce liquidity while earnings are negative.
Management's outlook
The supplied 10-Q text does not provide quantitative revenue or EPS guidance. The prior outlook was revenue exceeding $190.0 million for 2026, but this filing excerpt does not explicitly reaffirm or change it.
Earlier filings 4
10-Q · November 12, 2024
Biote reported Q3 revenue of $51.384M (three months ended Sept 30, 2024) and diluted EPS of $0.33, driven by product revenue of $49.806M and improved margins. Gross margin expanded to ~70.5% and operating margin to…
10-Q · August 15, 2022
biote Corp. reported quarterly revenue of $41,359 (amounts in thousands) for the three months ended June 30, 2022, up from $34,750 in the prior-year quarter, driven by product revenue of $40,789. Despite top-line growth…
10-Q · November 24, 2021
Haymaker Acquisition Corp. III reported net income of $2,995,085 for the three months ended September 30, 2021 (nine months net income $12,290,535), driven primarily by non‑operating fair value gains on warrant…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.